High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease

Scandinavian Journal of Rheumatology

Volumn 37, Issue 6, 2008, Pages 445-449

  Hoshina, T ^a   Kusuhara, K ^a   Ikeda, K ^a   Mizuno, Y ^b   Saito, M ^a   Hara, T ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA CHILDREN S HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CD74 ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; LYMPHOCYTE ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS;

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HMGB1 PROTEIN; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RECEPTORS, IMMUNOLOGIC; SEPSIS;

EID: 56249117683     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802144143     Document Type: Article

References (15)

1. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44.
2. Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol 2005;141:381-7.
3. + regulatory T cells in patients with Kawasaki disease. J Pediatr 2004;145:385-90.
4. Goodwin GH, Johns EW. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol 1977;16:257-67.
5. Harris HE, Andersson U. The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004;34:1503-12.
6. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153:80-2.
7. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000;20:751-62.
8. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-24.
9. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-28.
10. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
11. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001;99:373-7.
12. Lee TJ, Chun JK, Yeon SI, Shin JS, Kim DS. Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease. Scand J Rheumatol 2007;36:222-5.
13. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25:595-606.
14. Reimann T, Buscher D, Hipskind RA, Krautwald S, Lohmann-Matthes ML, Baccarini M. Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1beta and the TNF-α genes. J Immunol 1994;153:5740-9.
15. Stenbog EV, Windelborg B, Horlyck A, Herlin T. The effect of TNF-α blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol 2006;35:318-21.